Phreesia, Inc. (PHR) Stock Price & Analysis
Phreesia, Inc. (PHR) is trading at USD 12.32, down 1.91% today, as of November 18, 2026 at 20:57 UTC (US market open; quotes may be delayed), according to Nexqual market data.
PHR last closed at USD 12.56; today's session has ranged USD 12.04–12.95 on volume of 679,082 shares. Market capitalization is $764.71M, with a 52-week range of USD 7.77–21.24 (NYQ). Source: Nexqual, retrieved November 18, 2026 at 20:57 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PHR.md
Key facts (PHR)
- Last four reported quarters (through Jul 31, 2026): revenue $508M, net income $10.4M (2.1% margin), free cash flow $80.7M (SEC filings).
- Valuation: P/E 73.2x (avg 358.1x at the last 1 fiscal year-ends), EV/EBITDA 13.9x, net cash $73.5M.
- Earnings quality: non-operating income -$9.8M vs operating income $12.5M over the last four quarters; P/E excluding non-operating income ≈37.8x (estimate: non-operating income taxed at the company's 0% effective rate).
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $129K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.44 on a 1–5 scale) (18 analysts), mean target USD 13.87 (range 10–19).
- Total return with dividends: 1Y -37.1% vs S&P 500 +11.8%; 5Y -81.8% vs S&P 500 +66.5%.
- Next earnings: 2026-12-02, EPS estimate USD 0.35, revenue estimate $128M. All companies reporting that day: https://nexqual.com/earnings/2026-12-02
- Dividend: PHR paid no cash dividend in the last five years.
- Short interest: 5.99% of float (as of 2026-10-30), 4.6 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PHR)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $213M | $281M | $356M | $420M | $481M | $508M |
| Operating income | -$117M | -$177M | -$136M | -$58.1M | -$6.6M | $12.5M |
| Net income | -$118M | -$176M | -$137M | -$58.5M | $2.3M | $10.4M |
| EPS (diluted) | -$2.37 | -$3.36 | -$2.51 | -$1.02 | $0.04 | — |
| Free cash flow | -$93.1M | -$94.9M | -$38.2M | $23.7M | $67.7M | $80.7M |
| Operating margin | -54.8% | -62.9% | -38.3% | -13.8% | -1.4% | 2.5% |
| Net margin | -55.4% | -62.7% | -38.4% | -13.9% | 0.5% | 2.1% |
| Revenue growth | +43.4% | +31.7% | +26.8% | +17.8% | +14.5% | — |
| Cash + short-term investments | $314M | $177M | $87.5M | $84.2M | $73.8M | — |
| Total debt | $360K | $246K | $3.1M | $1.9M | $2.7M | — |
Fiscal years end Jan. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (PHR)
P/E 73.2x · P/E ex non-operating (est.) ≈37.8x · P/S 1.5x · EV/EBITDA 13.9x · EV/Sales 1.4x · P/FCF 9.5x · P/B 2.1x · FCF yield 10.56% · Earnings yield 1.37% · Net cash $73.5M · EV $691M
P/E at fiscal year-ends: Jan 2026 358.1x.
Insider sales (SEC Form 4, open-market, last ~7 months) (PHR)
6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Hoffman Allison C | General Counsel & Secretary | 6,662 | $67K | 2.4% | Yes (adopted December 19, 2025) | Routine (sold in Jan & Apr & Sep & Oct each year 2023–2025) |
| 2026-07-16 | Hui Yvonne | Principal Accounting Officer | 1,247 | $14K | 5.4% | Yes (adopted January 15, 2026) | Too little history (no open-market trades in 2023) |
| 2026-07-14 | Egbuonu-Davis Lisa | Director | 536 | $6K | 1.4% | Yes (adopted December 16, 2025) | Too little history (no open-market trades in 2023) |
| 2026-07-06 | Hui Yvonne | Principal Accounting Officer | 1,371 | $15K | 5.4% | Yes (adopted January 15, 2026) | Too little history (no open-market trades in 2023) |
| 2026-06-25 | Egbuonu-Davis Lisa | Director | 2,546 | $24K | 6.2% | Yes (adopted December 16, 2025) | Too little history (no open-market trades in 2023) |
| 2026-05-18 | Hui Yvonne | Principal Accounting Officer | 431 | $4K | 1.8% | Yes (adopted January 15, 2026) | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PHR)
Consensus Buy (mean 2.44 on a 1–5 scale), 18 analysts; mean target USD 13.87 (low 10, high 19).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-11 | JP Morgan | Downgrade | Neutral → Underweight | $13 |
| 2026-10-12 | Barclays | Target raised | Equal-Weight | $10 → $11 |
| 2026-09-08 | Raymond James | Downgrade | Outperform → Market Perform | |
| 2026-09-04 | DA Davidson | Target lowered | Buy | $14 → $13 |
| 2026-09-04 | Baird | Target raised | Neutral | $10 → $11 |
| 2026-09-03 | Freedom Capital Markets | Maintained | Buy | $14 |
| 2026-09-03 | RBC Capital | Reiterated | Outperform | $19 |
| 2026-09-03 | Wells Fargo | Target raised | Equal-Weight | $9 → $10 |
| 2026-09-03 | Canaccord Genuity | Maintained | Buy | $16 |
| 2026-09-03 | Needham | Reiterated | Buy | $14 |
| 2026-08-31 | Needham | Reiterated | Buy | $14 |
Total return (dividends reinvested) (PHR)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | -37.1% | -81.8% |
| S&P 500 (SPY) | +11.8% | +66.5% |
| Per year | -37.2% | -28.9% |
| Volatility (annualized) | 61.9% | 60.2% |
| Max drawdown | -60.9% (Nov 2025→Apr 2026) | -88.1% (Nov 2021→Apr 2026) |
Dividends (PHR)
PHR paid no cash dividend in the last five years.
Short interest (PHR)
3,021,990 shares sold short, 5.99% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 3,015,320 shares (+0.2%). Days to cover: 4.6 (short shares ÷ average daily volume).
PHR earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jul 31, 2026 | $0.28 | $0.32 | Miss −12.5% | — |
| — | Quarter ended Apr 30, 2026 | $0.27 | $0.29 | Miss −6.9% | — |
| — | Quarter ended Jan 31, 2026 | $0.44 | $0.32 | Beat +37.5% | — |
| — | Quarter ended Oct 31, 2025 | $0.31 | $0.24 | Beat +29.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
PHR recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 13, 2026 | Schedule 13G/A | AQR Capital Management, LLC, AQR Capital Management Holdings, LLC: 4.3% of shares, passive 5%+ holder (amended) |
| Oct 27, 2026 | Schedule 13G | BlackRock Portfolio Management LLC: 5.1% of shares, passive 5%+ holder |
| Sep 3, 2026 | 10-Q | Quarterly report · period ended Jul 31, 2026 |
| Sep 2, 2026 | 8-K | Quarterly results |
| Aug 12, 2026 | Schedule 13G | AQR Capital Management, LLC, AQR Capital Management Holdings, LLC: 5.1% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
PHR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Visa (V) | “We have developed partnerships with primary credit card processors in the United States to facilitate payment processing, and we are registered with Visa, MasterCard, American Express, Discover and other card networks as a service provider (payment facilitator or the equivalent) for acquiring member institutions.” |
Quoted from the company's 10-K filed Mar 31, 2026.
PHR company outlook (results filed Sep 2, 2026)
- “We are maintaining our revenue outlook for fiscal 2027.”
- “We expect revenue to be in the range of $510 million to $520 million.”
- “The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne (as defined below) and no additional revenue from potential future acquisitions completed between now and January 31, 2027.”
- “We are maintaining our Adjusted EBITDA outlook for fiscal 2027.”
Quoted word-for-word from the SEC 8-K results press release.
PHR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Oct 2026) | $0.35 | $0.36 | -0.2% | $128.4M | 10 |
| Next quarter (ends Jan 2027) | $0.35 | $0.37 | -5.5% | $126.9M | 10 |
| Current fiscal year (ends Jan 2027) | $1.26 | $1.33 | -4.9% | $515.7M | 10 |
| Next fiscal year (ends Jan 2028) | $1.58 | $1.61 | -1.6% | $534.6M | 9 |
Key Statistics (as of November 18, 2026 at 20:57 UTC)
| Price | USD 12.32 |
|---|---|
| Change | ▼ 1.91% (down) |
| Previous Close | USD 12.56 |
| Open | USD 12.42 |
| Day Range | USD 12.04 – 12.95 |
| 52-Week Range | USD 7.77 – 21.24 |
| Volume | 679,082 shares |
| Market Cap | $764.71M |
| Exchange | NYQ |
Technical Analysis (PHR)
Nexqual's technical model rates PHR "NEUTRAL" based on 3 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 20:57 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.23 (neutral) |
| vs SMA50 | Above (USD 11.35) |
| MACD | 0.32 (positive) |
Analyst Ratings (PHR)
Wall Street analysts rate PHR "Buy" based on 18 analysts, with a mean price target of USD 13.87 (range USD 10–19), per Nexqual as of November 18, 2026 at 20:57 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 13.87 |
| High Target | USD 19 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 10 / 7 / 1 |
Earnings (PHR)
| Next Earnings Date | 2026-12-02 |
|---|---|
| EPS Estimate | USD 0.35 |
| Revenue Estimate | $128.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD 0.28 vs est 0.32 ▼ miss |
| 2026-04-30 | USD 0.27 vs est 0.29 ▼ miss |
| 2026-01-31 | USD 0.44 vs est 0.32 ▲ beat |
| 2025-10-31 | USD 0.31 vs est 0.24 ▲ beat |
Source: Nexqual, November 18, 2026 at 20:57 UTC.
Financials & Fundamentals (PHR)
| Total Revenue | $507.79M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.40% |
| Gross Margin | +67.52% |
| Operating Margin | +4.29% |
| Profit Margin | +2.06% |
| ROE | +3.12% |
| Debt / Equity | 0.18 |
| Current Ratio | 1.76 |
| Total Cash | $72.94M |
| Total Debt | $67.95M |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $80.75M (15.9% of revenue) |
Source: Nexqual, November 18, 2026 at 20:57 UTC.
Financial Health Score (PHR)
Nexqual rates Phreesia, Inc.'s overall financial health "Solid" across five dimensions, as of November 18, 2026 at 20:57 UTC.
| Growth | Solid — Revenue +13% (last 4 quarters to Jul 2026 vs the 4 before, SEC) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 2% (last 12 months) |
| Balance Sheet | Strong — $75M cash and investments vs $1M debt (Jul 2026, SEC), net cash |
| Cash Flow | Strong — FCF $81M (last 4 quarters to Jul 2026, SEC), 16% margin |
| Efficiency | Weak — ROE 3%, ROA 1.6% (last 4 quarters, SEC) |
Ownership (PHR)
| Insider Ownership | +6.35% |
|---|---|
| Institutional Ownership | +95.28% |
| Shares Outstanding | 62.07M |
| Float | 49.23M |
| Short % of Float | +5.99% |
Source: Nexqual, November 18, 2026 at 20:57 UTC.
Leadership (PHR)
Phreesia, Inc. is led by Chaim Indig, Co-Founder, CEO & Director, per Nexqual as of November 18, 2026 at 20:57 UTC.
| Co-Founder, CEO & Director | Chaim Indig |
|---|---|
| Co-Founder & President of Provider Solutions | Evan Roberts |
| Chief Financial Officer | Balaji Gandhi |
| President of Network Solutions | David Linetsky |
| Chief Technology Officer | Jack Callahan |
Major Backers & Investors (PHR)
Notable institutional backers of Phreesia, Inc. include Pale Fire Capital SE, AQR Capital Management, LLC, Acadian Asset Management. LLC, according to Nexqual as of November 18, 2026 at 20:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pale Fire Capital SE | 14.38% |
| AQR Capital Management, LLC | 5.08% |
| Acadian Asset Management. LLC | 2.35% |
| Goldman Sachs | 2.31% |
| T. Rowe Price | 2.09% |
| Algert Global, LLC | 1.94% |
| Fidelity | 1.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.49% |
| Vanguard Group | 9.26% |
| State Street | 2.55% |
Source: Nexqual, November 18, 2026 at 20:57 UTC.
From Phreesia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- We have industry certifications, including HITRUST, PCI-DSS Level 1 Service Provider, Systems and Organization Controls 2 ("SOC 2") and PCI Point-to-Point Encryption.
- In fiscal year 2026, our platform facilitated approximately 180 million patient visits, representing approximately one in six ambulatory patient visits in the United States.
- Phreesia's integrated platform is designed to address challenges patients and healthcare providers face in three core areas: Access, Affordability, and Outcomes.
- Our continued growth and success depend, in part, on our ability to protect our intellectual property and proprietary technology.
Legal & Regulatory Risks (Item 1A, quoted)
- Privacy concerns, cyber-attacks, data breaches or cybersecurity incidents relating to our solutions could result in economic loss, damage to our reputation, deterrence of users from using our products, and exposure to legal penalties and liability.
- Changes in laws and regulations relating to interchange fees on payment card transactions, or increases in card network fees and other changes to fee arrangements, may result in the loss of clients who use our payment processing services and would adversely affect our revenue and results of operations.
- Our use of "open source" software could adversely affect our ability to offer our services and subject us to possible litigation.
- We conduct business in a heavily regulated industry in an uncertain and evolving political and regulatory environment, and any failure to comply with applicable healthcare laws and government regulations could result in financial penalties, adverse regulatory action and adverse publicity, or could require us to make significant operational changes, any of which could harm our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HQY | HealthEquity, Inc. | USD 97.37 | ▼ 4.39% |
| HSTM | HealthStream, Inc. | USD 26.93 | ▼ 2.53% |
| OMDA | Omada Health, Inc. | USD 13.18 | ▼ 6.43% |
| SOPH | SOPHiA GENETICS SA | USD 7.47 | ▲ 0.2% |
| NRC | NRC Health | USD 26.11 | ▲ 0.87% |
| CARL | Carlsmed, Inc. | USD 17.32 | ▼ 2.37% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:57 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt